|
🐜
|
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
9 auth.
S. Trudel,
Zhi Hua Li,
E. Wei,
M. Wiesmann,
Hong Chang,
Christine I. Chen,
...
D. Reece,
C. Heise,
A. Stewart
|
8 |
2004 |
8
🐜
|
|
🐜
|
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
17 auth.
Christine I. Chen,
P. Bergsagel,
Harminder K Paul,
W. Xu,
A. Lau,
N. Dave,
V. Kukreti,
E. Wei,
Chungyee Leung-Hagesteijn,
Zhi Hua Li,
...
Joseph M. Brandwein,
Mariela Pantoja,
J. Johnston,
S. Gibson,
Tiffany A. Hernandez,
D. Spaner,
S. Trudel
|
7 |
2011 |
7
🐜
|
|
🐜
|
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
11 auth.
S. Trudel,
A. Stewart,
E. Rom,
E. Wei,
Zhi Hua Li,
Sarit Kotzer,
...
I. Chumakov,
Y. Singer,
Hong Chang,
S. Liang,
A. Yayon
|
7 |
2006 |
7
🐜
|
|
🐜
|
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
11 auth.
E. Masih-Khan,
S. Trudel,
C. Heise,
Zhi-hua Li,
Joshua Paterson,
Vincent Nadeem,
...
E. Wei,
D. Roodman,
J. Claudio,
P. Bergsagel,
A. Stewart
|
6 |
2006 |
6
🐜
|
|
🐜
|
The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades
10 auth.
Yuan-Xiao Zhu,
S. Benn,
Zhi Hua Li,
E. Wei,
E. Masih-Khan,
Y. Trieu,
...
Meenakshi Bali,
C. McGlade,
J. Claudio,
A. Stewart
|
5 |
2004 |
5
🐜
|
|
🐜
|
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).
10 auth.
Christine I. Chen,
Harminder K Paul,
W. Xu,
V. Kukreti,
S. Trudel,
E. Wei,
...
Zhi Hua Li,
Joseph M. Brandwein,
Mariela Pantoja,
Chungyee Leung-Hagensteijn
|
5 |
2007 |
5
🐜
|
|
🐜
|
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression
12 auth.
Danielle C. Croucher,
Laura M. Richards,
Serges P. Tsofack,
Daniel D Waller,
Zhi-hua Li,
E. Wei,
...
X. Huang,
M. Chesi,
P. Bergsagel,
M. Sebag,
Trevor J Pugh,
S. Trudel
|
4 |
2021 |
4
🐜
|
|
🐜
|
Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium
15 auth.
S. Trudel,
N. Bahlis,
C. Venner,
A. Hay,
Olena Kis,
Signy Chow,
Zhi Hua Li,
E. Wei,
Lisa Wang,
C. Tran,
...
S. Udagani,
C. Blattler,
Trevor J Pugh,
Helen X. Chen,
A. Oza
|
4 |
2016 |
4
🐜
|
|
🐜
|
The inhibitory anti-FGFR 3 antibody , PRO-001 , is cytotoxic to t ( 4 ; 14 ) multiple myeloma cells
11 auth.
S. Trudel,
A. Stewart,
E. Rom,
E. Wei,
Zhi Hua Li,
Sarit Kotzer,
...
I. Chumakov,
Y. Singer,
Hong Chang,
S. Liang,
A. Yayon
|
3 |
2006 |
3
🐜
|
